Ningbo Tianyi Medical Appliance (301097)

Search documents
机构风向标 | 天益医疗(301097)2025年二季度已披露持仓机构仅7家
Xin Lang Cai Jing· 2025-08-28 10:33
Summary of Key Points Core Viewpoint - Tianyi Medical (301097.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 1.559 million shares held by seven institutions, representing 2.64% of the total share capital, down by 0.38 percentage points from the previous quarter [1]. Institutional Holdings - As of August 27, 2025, seven institutional investors disclosed their holdings in Tianyi Medical, totaling 1.559 million shares, which is 2.64% of the company's total equity [1]. - The institutional investors include notable funds such as China Merchants Bank - Penghua Hongjia Flexible Allocation Mixed Fund and China Construction Bank - Yuanxin Yongfeng聚优 Equity Fund [1]. - The total institutional holding percentage decreased by 0.38 percentage points compared to the previous quarter [1]. Public Fund Holdings - Two public funds reduced their holdings compared to the previous quarter, specifically Yuanxin Yongfeng Medical Health A and Yuanxin Yongfeng聚优 A, with a total reduction of 0.12% [1]. - One new public fund disclosed its holdings during this period, which is the Rongtong Health Industry Flexible Allocation Mixed A/B [1]. - One public fund, Penghua Quality Governance Mixed (LOF) A, was not disclosed in this quarter compared to the previous one [1].
宁波天益医疗器械股份有限公司2025年半年度报告摘要
Shang Hai Zheng Quan Bao· 2025-08-28 08:59
Core Viewpoint - The company has reported its 2025 semi-annual results, highlighting key financial metrics and strategic initiatives, including share repurchase plans and stock incentive programs, while maintaining compliance with regulatory requirements [1][17][31]. Company Overview - The company, Ningbo Tianyi Medical Instruments Co., Ltd., has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4]. - The company plans to repurchase shares using its own funds, with a total repurchase amount between RMB 30 million and RMB 60 million, targeting a maximum price of RMB 50.00 per share [3][5]. Financial Data and Indicators - The company completed a share repurchase of 1,427,400 shares, representing 2.42% of its total share capital, with a total transaction amount of approximately RMB 57.64 million [5]. - The company has approved a stock incentive plan to grant 2.343 million restricted stocks to eligible employees, with a grant price of RMB 22.11 per share [6][7]. Important Events - The company has engaged in a joint investment with an affiliate to acquire CRRT business assets for EUR 43.54 million, with the transaction completed in February 2025 [9][10]. - The company is in the process of establishing an overseas production base in Thailand, reallocating funds from a previously planned project to support this initiative [11][12]. Fundraising and Usage - The company raised a total of RMB 771.77 million from its public offering, with a net amount of RMB 694.56 million after deducting fees [43]. - As of June 30, 2025, the company has nine dedicated fundraising accounts and has utilized RMB 60 million for cash management, including structured deposits and large certificates of deposit [44][45]. Compliance and Reporting - The board and supervisory committee have unanimously approved the semi-annual report and the special report on the use of raised funds, confirming compliance with relevant regulations [22][35].
天益医疗:第三届董事会第二十五次会议决议公告
Zheng Quan Ri Bao· 2025-08-27 12:24
Group 1 - The core point of the article is that Tianyi Medical announced the approval of multiple proposals during the 25th meeting of its third board of directors [2] Group 2 - The announcement was made on the evening of August 27 [2] - The meeting involved the review of the company's proposals [2]
天益医疗:第三届监事会第二十一次会议决议公告
Zheng Quan Ri Bao· 2025-08-27 12:23
Core Viewpoint - Tianyi Medical announced the approval of company-related proposals during the 21st meeting of its third supervisory board on the evening of August 27 [2] Group 1 - The company held a supervisory board meeting to discuss and approve important proposals [2]
天益医疗:2025年半年度净利润约948万元
Sou Hu Cai Jing· 2025-08-27 09:55
Company Performance - Tianyi Medical reported a revenue of approximately 227 million yuan for the first half of 2025, representing a year-on-year increase of 11.5% [1] - The net profit attributable to shareholders of the listed company was approximately 9.48 million yuan, showing a year-on-year decrease of 35.23% [1] - Basic earnings per share were 0.16 yuan, reflecting a year-on-year decline of 46.67% [1] Industry Insights - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]
天益医疗:8月27日召开董事会会议
Sou Hu Cai Jing· 2025-08-27 09:55
Group 1 - The company Tianyi Medical announced the convening of its 25th meeting of the third board of directors on August 27, 2025, to review the proposal regarding the 2025 semi-annual report and its summary [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1]
天益医疗(301097.SZ):上半年净利润948.32万元 同比下降35.23%
Ge Long Hui A P P· 2025-08-27 08:28
Group 1 - The company reported a revenue of 227 million yuan for the first half of 2025, representing a year-on-year growth of 11.50% [1] - The net profit attributable to shareholders of the listed company was 9.48 million yuan, a year-on-year decrease of 35.23% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.04 million yuan, a year-on-year decrease of 84.63% [1] - The basic earnings per share were 0.16 yuan [1]
天益医疗(301097) - 2025年半年度募集资金存放与使用情况专项报告
2025-08-27 08:17
证券代码:301097 证券简称:天益医疗 公告编号:2025-044 宁波天益医疗器械股份有限公司 2025 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》(证监会公告 〔2025〕10 号)和深圳证券交易所印发的《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作(2025 年修订)》(深证上〔2025〕 481 号)的规定,将本公司募集资金 2025 年半年度存放与使用情况专项说明如 下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发行股票注册的批复》(证监许可〔2021〕3939 号),本公司由主承销 商国泰君安证券股份有限公司采用余额包销方式,向社会公众公开发行人民币普 通股(A 股)股票 1,473.68 万股,发行价为每股人民币 52.37 元,共计募集资 金 77,176.84 万元,坐扣承销和保荐费用 5,916.93 万元后的募集资 ...
天益医疗(301097) - 监事会决议公告
2025-08-27 08:16
一、监事会会议召开情况 2025年8月27日,宁波天益医疗器械股份有限公司("公司")第三届监事会 第二十一次会议在公司会议室召开。本次会议由陈云俊主持。应出席监事3名, 亲自出席监事3名。符合《公司章程》规定的法定人数,本次监事会会议决议合 法有效。 证券代码:301097 证券简称:天益医疗 公告编号:2025-041 宁波天益医疗器械股份有限公司 第三届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 经与会监事审议表决,一致通过如下议案: 1、审议通过了《关于公司<2025年半年度报告及其摘要>的议案》 监事会认为:董事会编制和审核公司2025年半年度报告及其摘要的内容真实、 准确、完整地反映了公司2025年半年度经营的实际情况,不存在虚假记载、误导 性陈述或者重大遗漏;报告的编制和审核程序符合法律、行政法规的要求,符合 中国证监会及深圳证券交易所的相关规定。 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 表决结果:3票同意、0票反对、0票弃权,0票回避表决。 本议 ...
天益医疗(301097) - 董事会决议公告
2025-08-27 08:15
证券代码:301097 证券简称:天益医疗 公告编号:2025-040 宁波天益医疗器械股份有限公司 第三届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 经与会董事审议表决,一致通过如下议案: 1、审议通过了《关于公司<2025 年半年度报告及其摘要>的议案》 公司董事会在全面审核公司 2025 年半年度报告全文及其摘要后,认为公司 2025 年半年度报告及其摘要的内容真实、准确、完整地反映了公司 2025 年半年 度经营的实际情况,不存在虚假记载、误导性陈述或者重大遗漏;报告的编制和 审核程序符合法律、行政法规的要求,符合中国证监会及深圳证券交易所的相关 规定,同意对外报出。 本议案已经公司第三届董事会审计委员会 2025 年第三次会议审议通过。 具体内容详见同日在中国证监会指定创业板信息披露网站巨潮资讯网上发 布的相关公告。 表决结果:7 票同意、0 票反对、0 票弃权,0 票回避表决。 本议案无需提交公司股东会审议。 2、审议通过了《关于公司<2025 年半年度募集资金存放与 ...